relatlimab,nivolumab
bms
['melanoma', 'nivo', '047,(-nct047),(-0.047%)', 'nivolumab', 'relativity-047', 'relatlimab']
additional response outcomes from relativity-047 show numerically higher response rates for patients with metastatic or unresectable melanoma treated with nivolumab plus relatlimab compared to nivolumab alone: #esmo22 #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789